A detailed history of Parallel Advisors, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,891 shares of ITCI stock, worth $157,161. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,891
Previous 1,614 17.16%
Holding current value
$157,161
Previous $110,000 25.45%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$67.99 - $80.84 $18,833 - $22,392
277 Added 17.16%
1,891 $138,000
Q2 2024

Aug 08, 2024

BUY
$64.76 - $79.84 $971 - $1,197
15 Added 0.94%
1,614 $110,000
Q1 2024

May 06, 2024

BUY
$64.37 - $75.65 $2,252 - $2,647
35 Added 2.24%
1,599 $110,000
Q4 2023

Feb 09, 2024

BUY
$46.37 - $73.65 $10,155 - $16,129
219 Added 16.28%
1,564 $112,000
Q3 2023

May 20, 2024

BUY
$52.09 - $64.1 $5,886 - $7,243
113 Added 9.17%
1,345 $70,000
Q3 2023

Nov 13, 2023

BUY
$52.09 - $64.1 $5,886 - $7,243
113 Added 9.17%
1,345 $70,000
Q1 2023

May 20, 2024

SELL
$43.8 - $56.99 $16,074 - $20,915
-367 Reduced 22.95%
1,232 $66,000
Q1 2023

Apr 25, 2023

SELL
$43.8 - $56.99 $55,713 - $72,491
-1,272 Reduced 50.8%
1,232 $66,000
Q4 2022

Feb 03, 2023

SELL
$44.07 - $54.45 $132 - $163
-3 Reduced 0.12%
2,504 $132,000
Q3 2022

Nov 10, 2022

BUY
$42.7 - $59.99 $128 - $179
3 Added 0.12%
2,507 $117,000
Q2 2022

Aug 01, 2022

SELL
$43.0 - $65.64 $946 - $1,444
-22 Reduced 0.87%
2,504 $143,000
Q1 2022

Apr 28, 2022

SELL
$38.74 - $62.09 $4,571 - $7,326
-118 Reduced 4.46%
2,526 $152,000
Q4 2021

Jan 20, 2022

SELL
$35.2 - $53.42 $211 - $320
-6 Reduced 0.23%
2,644 $138,000
Q3 2021

Nov 02, 2021

BUY
$28.72 - $42.49 $4,308 - $6,373
150 Added 6.0%
2,650 $99,000
Q3 2020

Oct 27, 2020

BUY
$17.61 - $31.86 $44,025 - $79,650
2,500 New
2,500 $64,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.